VRDN (viridiantherapeutics.com) Rasio Nilai Pasar marang Nilai Buku

Simbol resmi perusahaan Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics (VRDN) is a biotech startup with volatile cash flows that relies on external financing due to a lack of regular sales. This trading chart, with the metric at 4.87, highlights the dynamics of a company developing safe IGF-1R antibodies for the therapy of ocular pathologies associated with thyroid diseases. The business currently operates on the momentum of scientific research while awaiting the completion of clinical trials for its innovative products.

VRDN Viridian Corp: Nilai Pasar marang Nilai Buku ing interval 04.07.2022 - 28.10.2026

Rincian metrik keuangan lan pasar Viridian Therapeutics Inc (VRDN)

- rega lan prakiraan konsensus rega:
Bagan rega Viridian Therapeutics|VRDN - Prakiraan gabungan firma investasi
- data kapitalisasi pasar:
Nilai pasar Viridian Pharma|VRDN - Nilai Wutuh Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham Viridian Therapeutics|VRDN - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku viridiantherapeutics.com|VRDN - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Viridian Therapeutics|VRDN - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Viridian Pharma|VRDN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Viridian Pharma|VRDN - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Viridian Therapeutics
Analisis wiwitan perusahaan:Viridian Therapeutics - VRDN
Produk asli Viridian Pharma

Amid intense competition in the ophthalmology sector, where the value of Viridian Therapeutics (VRDN) depends on the outcome of clinical trials, market capitalization often decouples from tangible assets. The market-to-book premium ratio measures this discrepancy, showing the extent to which the market overvalues the company's net equity relative to its book value, reflecting either investor confidence in future breakthroughs or the risk of being overbought.

Pesaing utama

Rasio Nilai Pasar marang Nilai Buku Alcon Inc.|BLCO (bausch.com) - Rasio Kapitalisasi marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Glaukos GKOS|Kapitalisasi Pasar marang Aset Bersih Apellis Pharmaceuticals, Inc.|Belite Bio, Inc. (BLTE) - Rasio Kapitalisasi Pasar marang Nilai Buku|Nilai Pasar marang Nilai Buku Ocular Pharma (OCUL)|Rasio Kapitalisasi Pasar marang Nilai Buku HROW (Harrow, Inc.)|lenz-tx.com - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Oaktree Specialty Lending (OCS)|EYPT: Nilai Pasar marang Nilai Buku|KOD (Kodiak Pharma) - Rasio Nilai Pasar marang Nilai Buku|Aldeyra Therapeutics, Inc. (ALDX) - Rasio Kapitalisasi marang Aset Bersih|KALA (KALA BIO Inc.) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku Opus Bio (IRD)|OKYO Pharma Limited (OKYO) - Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku adverum.com (ADVM)|OTLK: Rasio Kapitalisasi Pasar marang Nilai Buku|CLSD - Koefisien Nilai Pasar marang Nilai Buku|NBY (NovaBay) - Rasio Kapitalisasi marang Aset Bersih|KPRX - Koefisien Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku ALIM|EYEN (Eyenovia) - Koefisien Nilai Pasar marang Nilai Buku|GHSI: Rasio Nilai Pasar marang Nilai Buku|Kapitalisasi Pasar marang Nilai Buku Ocuphire Corporation (OCUP)|Rasio Kapitalisasi marang Aset Bersih Opthea Limited (OPT)